Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Urologic Diseases 1 Nephritis 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Kidney Diseases 1 Immune System Diseases 1 Heart Failure 1 Glomerulonephritis, IGA 1 Glomerulonephritis 1 Cardiomyopathies 1 Autoimmune Diseases 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 3 Nutrition Assessment 3 Exercise 3 Carvedilol 3 dapagliflozin 2 Standard of Care 2 Rituximab 2 Ivabradine 2 Control Groups 2 Atorvastatin 2 pertuzumab 1 pegfilgrastim 1 obinutuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 candesartan 1 acalabrutinib 1 Vincristine 1 Valsartan 1 Trastuzumab 1 Surveys and Questionnaires 1 Spironolactone 1 Sodium Chloride 1 Simendan 1 Secondary Prevention 1 Resistance Training 1 Pyruvic Acid 1 Prednisolone 1 Practice Guidelines as Topic 1 Population Groups 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Heart Failure × Valsartan × Clear all

NCT05194111 2026-03-13

TREAT-HF

Virginia Commonwealth University

Phase 1/2 Recruiting

Heart Failure

Data powered by HemOnc (CC BY 4.0) Colophon ⚡